Aristolactam I
Aristolactam I is an AQP1 inhibitor and Aristolochic acid I metabolite. Aristolactam I can be isolated from Aristolochia plants. Aristolactam I downregulates Twist1 expression, increases E-cadherin expression, and activates the TGF-β/Smad signaling pathway. Aristolactam I has anticancer activity against breast cancer. Aristolactam I is nephrotoxic. Aristolactam I is mainly used in the study of breast cancer and kidney diseases such as renal interstitial fibrosis[1][2][3][4][5].
Product Specifications
CAS Number
13395-02-3
Product Name Alternative
Aristololactam; Aristolactam
UNSPSC
12352005
Hazard Statement
H300+H310+H330, H341, H351
Target
Aquaporin; Cadherin; Drug Metabolite; TGF-beta/Smad
Type
Natural Products
Related Pathways
Cytoskeleton; Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease; Stem Cell/Wnt; TGF-beta/Smad
Applications
COVID-19-immunoregulation
Field of Research
Cancer; Endocrinology
Assay Protocol
https://www.medchemexpress.com/aristolactam-i.html
Purity
99.44
Solubility
DMSO : 12.5 mg/mL (ultrasonic) |H2O : < 0.1 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
O=C1NC2=C(C3=C4C(C(OC)=CC=C4)=C2)C1=CC5=C3OCO5
Molecular Formula
C17H11NO4
Molecular Weight
293.27
Precautions
H300+H310+H330, H341, H351
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, protect from light)
Scientific Category
Natural Products
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Recombinant Carcinoscorpius rotundicauda Limulus clotting factor C, partial
Recombinant Carcinoscorpius rotundicauda Limulus clotting factor C, partial
Recombinant Carcinoscorpius rotundicauda Limulus clotting factor C, partial
Recombinant Carcinoscorpius rotundicauda Limulus clotting factor C, partial
Recombinant Carcinoscorpius rotundicauda Limulus clotting factor C, partial